From the Basics to Next Line Therapy: ALK + NSCLC
Podcast | English | 46 Min
Image For Activity Cover
Cost
$0.00
Credit
No Credit Offered

ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers, but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from Vanderbilt University and Yvonne Diaz from Oncogene Cancer Research discuss how an ALK-positive diagnosis is made and what therapies are currently available to treat it.

Podcast Hosts:
  • Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA 

Podcast Guests: 

  • Yvonne Diaz, Patient Advocate, Co-Founder, Oncogene Cancer Research, London, UK
  • Christine Lovly, MD, Associate Professor of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
Powered By